KYMRIAH

novartis pharmaceuticals canada inc🇨🇦 Health Canada

Approval Id: fb86af6785e16223
Drug Approval Canada Name: KYMRIAH
Product Name: KYMRIAH
Status: Marketed
Status Date: 2019-05-24
Original Market Date: 2019-05-24
Din: 02480514
Drug Class: Human
Dosage Form: Suspension
Route Of Administration: Intravenous
Schedule: Prescription , Schedule D
Ahfs: 26:12.00
Atc Original: L01XL04 TISAGENLECLEUCEL
Atc Name: l 01 xl 04
Aig Number: 0160630001
Company Name: novartis pharmaceuticals canada inc
Company Address: 100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1

TISAGENLECLEUCEL

600000000 CELLS

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

fb86af6785e16223

Type

Standard